Health Desk-- 26 June, 2018: US regulators on Monday approved the first marijuana-derived drug ever to hit the US market, Epidiolex, which will be used to treat two rare and severe forms of childhood epilepsy.
Made by the British biopharma company GW Pharmaceuticals, Epidiolex uses purified cannabidiol, or CBD, which is one of more than 80 active compounds in the cannabis sativa plant, often known simply as marijuana.
"This is an important medical advance," said US Food and Drug Administration Commissioner Scott Gottlieb.
"But it's also important to note that this is not an approval of marijuana or all of its components. This is the approval of one specific CBD medication for a specific use."
The drug is approved for use against Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older, the FDA said.